Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

1. Comparative efficacy and safety of traditional Chinese medicine injections combined with chemotherapy for advanced non-small cell lung cancer: a Bayesian network meta-analysis.Frontiers in immunology · 2026
   Pooled it
2. Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials.Clinical and experimental medicine · 2025
   Pooled it
3. Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis.European journal of clinical pharmacology · 2025
   Pooled it
4. Model-informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records.British journal of clinical pharmacology · 2026
   Article
5. Risk Factors and Comparative Safety of Anti-PD-1 Combination Therapies in Advanced Melanoma: A Nationwide Real-World Cohort Study From China.Cancer medicine · 2026
   Article
6. Immune checkpoint inhibitors combined with chemotherapy enhance coagulation activation and elevate venous thromboembolism risk in non-small cell lung cancer.American journal of cancer research · 2026
   Article
7. Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review-NEW Group (Neutropenic Events Working Group).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
   Article
8. Hematological toxicity of immune checkpoint inhibitors: a pharmacovigilance study.BMC cancer · 2025
   Article
9. Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.Immunotherapy · 2025
   Article
10. Evaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study.International journal of clinical oncology · 2025
    Article
11. Immunotherapy in the perioperative management of esophageal squamous cell carcinoma: recent developments.Frontiers in oncology · 2025
    Review
12. Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor.Journal of personalized medicine · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as